Regenxbio (RGNX)
8.69
+0.16 (1.88%)
Upcoming Events
Latest Headlines
Form 4 REGENXBIO Inc. For: Aug 25 Filed by: Ciongoli Gregory Austin
August 27, 2026 7:04 PM - SEC Filing
Form 3 REGENXBIO Inc. For: Aug 25 Filed by: Ciongoli Gregory Austin
August 27, 2026 7:02 PM - SEC Filing
Regenxbio Inc. (RGNX) PT Lowered to $21 at H.C. Wainwright
August 26, 2026 6:41 AM - StreetInsider
Form 8-K REGENXBIO Inc. For: Aug 25
August 25, 2026 4:57 PM - SEC Filing
RegenxBio adds new board member as two directors retire
August 25, 2026 7:05 AM - StreetInsider
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
August 25, 2026 7:05 AM - PR NewsWire
Regenxbio Inc. (RGNX) PT Lowered to $29 at Baird
August 25, 2026 6:18 AM - StreetInsider
Form 8-K REGENXBIO Inc. For: Aug 24
August 24, 2026 5:20 PM - SEC Filing
Regenxbio (RGNX) to Resume Trading at 7:25 am ET
August 24, 2026 7:13 AM - StreetInsider
FDA places clinical hold on Regenxbio's RGX-121 gene therapy for Hunter Syndrome
August 24, 2026 7:05 AM - StreetInsider
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
August 24, 2026 7:05 AM - PR NewsWire
Regenxbio Inc. (RGNX) PT Lowered to $23 at H.C. Wainwright
August 10, 2026 6:49 AM - StreetInsider
Barclays Downgrades Regenxbio Inc. (RGNX) to Equalweight
August 7, 2026 3:32 AM - StreetInsider
Barclays Downgrades Regenxbio Inc. (RGNX) to Equalweight
August 7, 2026 3:32 AM - StreetInsider
Regenxbio (RGNX) Tops Q2 EPS by 18c
August 6, 2026 7:39 AM - StreetInsider
Form 10-Q REGENXBIO Inc. For: Jun 30
August 6, 2026 7:16 AM - SEC Filing
Form 8-K REGENXBIO Inc. For: Aug 06
August 6, 2026 7:10 AM - SEC Filing
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
August 6, 2026 7:05 AM - PR NewsWire
Form 4 REGENXBIO Inc. For: Aug 01 Filed by: PAKOLA STEVE
August 4, 2026 4:32 PM - SEC Filing
Form 4 REGENXBIO Inc. For: Aug 01 Filed by: Christmas Patrick J.
August 4, 2026 4:30 PM - SEC Filing
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
August 3, 2026 7:05 AM - PR NewsWire
Regenxbio (RGNX) call put ratio 5.2 calls to 1 put with a focus on August 12 calls
July 22, 2026 3:58 AM - StreetInsider
Form 8-K REGENXBIO Inc. For: Jul 16
July 20, 2026 7:34 AM - SEC Filing
Regenxbio shares long-term gene therapy data for eye diseases
July 20, 2026 3:19 AM - StreetInsider
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
July 18, 2026 2:55 PM - PR NewsWire
Form 424B5 REGENXBIO Inc.
July 17, 2026 5:30 PM - SEC Filing
Regenxbio prices $100M public offering of stock and warrants
July 17, 2026 7:00 AM - StreetInsider
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
July 17, 2026 7:00 AM - PR NewsWire
Form FWP REGENXBIO Inc. Filed by: REGENXBIO Inc.
July 17, 2026 6:03 AM - SEC Filing
After-Hours Stock Movers: NFLX, ISRG, KO, AA, RGNX
July 16, 2026 4:44 PM - StreetInsider
Form 424B5 REGENXBIO Inc.
July 16, 2026 4:32 PM - SEC Filing
Regenxbio plans $100M common stock public offering
July 16, 2026 4:27 PM - StreetInsider
REGENXBIO Announces Proposed Public Offering of Common Stock
July 16, 2026 4:26 PM - PR NewsWire
Form 4 REGENXBIO Inc. For: Dec 31 Filed by: Simpson Curran
July 6, 2026 4:52 PM - SEC Filing
Form 4 REGENXBIO Inc. For: Jul 02 Filed by: PAKOLA STEVE
July 6, 2026 4:51 PM - SEC Filing
Form SC TO-I/A REGENXBIO Inc. Filed by: REGENXBIO Inc.
July 6, 2026 8:01 AM - SEC Filing
Form 4 REGENXBIO Inc. For: Jun 29 Filed by: PAKOLA STEVE
July 1, 2026 8:09 PM - SEC Filing
Form 144 REGENXBIO Inc. Filed by: PAKOLA STEVE
July 1, 2026 4:32 PM - SEC Filing
Form SC TO-I/A REGENXBIO Inc. Filed by: REGENXBIO Inc.
July 1, 2026 9:11 AM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
July 1, 2026 7:00 AM - StreetInsider
Form 8-K REGENXBIO Inc. For: Jun 23
June 29, 2026 7:15 AM - SEC Filing
Regenxbio doses first patient in diabetic retinopathy gene therapy trial
June 29, 2026 7:05 AM - StreetInsider
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
June 29, 2026 7:05 AM - PR NewsWire
H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
June 25, 2026 6:49 AM - StreetInsider
RegenxBio completes dosing in RGX-202 confirmatory Duchenne study
June 24, 2026 7:05 AM - StreetInsider
REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026
June 24, 2026 7:05 AM - PR NewsWire
H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
June 23, 2026 6:51 AM - StreetInsider
Regenxbio Inc. (RGNX) PT Raised to $18 at Leerink
June 22, 2026 10:21 AM - StreetInsider
Regenxbio Inc. (RGNX) PT Raised to $32 at Baird
June 22, 2026 9:50 AM - StreetInsider
FDA aligns with Regenxbio on path to refile MPS II gene therapy BLA
June 22, 2026 7:31 AM - StreetInsider
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
June 22, 2026 7:30 AM - PR NewsWire
Regenxbio shares jump after FDA agrees to reverse drug rejection
June 22, 2026 6:43 AM - StreetInsider
Full Article List
